首页 > 最新文献

Current Opinion in Pulmonary Medicine最新文献

英文 中文
The role of oscillometry in asthma. 振荡测量法在哮喘中的作用。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-15 DOI: 10.1097/MCP.0000000000001057
Patrick A Donohue, David A Kaminsky

Purpose of review: Oscillometry is a noninvasive pulmonary function test that has gained significant interest in the evaluation of lung disease. Currently, oscillometry is primarily a research tool, but there is a growing body of evidence supporting its clinical use. This review describes the recent work evaluating the role of oscillometry in the diagnosis and treatment of asthma.

Recent findings: A large body of observational data supports the ability of oscillometry to distinguish healthy individuals from those with respiratory symptoms or lung disease. Oscillometry may not be as useful as an isolated diagnostic test in asthma, but the combination with other pulmonary function tests may improve its diagnostic ability. Oscillometry can detect peripheral airways dysfunction in asthma, which is associated with symptoms and the risk for exacerbations. To help guide future research, minimal clinically important differences for specific oscillometry variables have been developed. Oscillometry may be useful in monitoring the response to biological therapy and has potential for personalizing treatment for individual patients. Oscillometry also has potential in uncovering unique aspects of the pathophysiology of asthma in obesity.

Summary: Oscillometry is a promising tool in the diagnosis and management of asthma. More research is needed to support its routine clinical use.

审查目的:振荡测定法是一种无创肺功能测试,在肺部疾病评估中已获得了极大的关注。目前,示波法主要是一种研究工具,但越来越多的证据支持其临床应用。本综述介绍了最近对示波法在哮喘诊断和治疗中的作用进行评估的工作:大量观察性数据支持示波法区分健康人和有呼吸道症状或肺部疾病的人的能力。振荡测定法作为一项单独的哮喘诊断测试可能并不实用,但与其他肺功能测试结合使用可提高其诊断能力。振荡测定法可以检测哮喘患者的外周气道功能障碍,这与症状和病情加重的风险有关。为了帮助指导未来的研究,已针对特定振荡测量变量制定了最小临床重要差异。振荡测量法可用于监测对生物疗法的反应,并有可能为个别患者提供个性化治疗。振荡测量法还有可能揭示肥胖症哮喘病理生理学的独特方面。需要更多的研究来支持其常规临床应用。
{"title":"The role of oscillometry in asthma.","authors":"Patrick A Donohue, David A Kaminsky","doi":"10.1097/MCP.0000000000001057","DOIUrl":"10.1097/MCP.0000000000001057","url":null,"abstract":"<p><strong>Purpose of review: </strong>Oscillometry is a noninvasive pulmonary function test that has gained significant interest in the evaluation of lung disease. Currently, oscillometry is primarily a research tool, but there is a growing body of evidence supporting its clinical use. This review describes the recent work evaluating the role of oscillometry in the diagnosis and treatment of asthma.</p><p><strong>Recent findings: </strong>A large body of observational data supports the ability of oscillometry to distinguish healthy individuals from those with respiratory symptoms or lung disease. Oscillometry may not be as useful as an isolated diagnostic test in asthma, but the combination with other pulmonary function tests may improve its diagnostic ability. Oscillometry can detect peripheral airways dysfunction in asthma, which is associated with symptoms and the risk for exacerbations. To help guide future research, minimal clinically important differences for specific oscillometry variables have been developed. Oscillometry may be useful in monitoring the response to biological therapy and has potential for personalizing treatment for individual patients. Oscillometry also has potential in uncovering unique aspects of the pathophysiology of asthma in obesity.</p><p><strong>Summary: </strong>Oscillometry is a promising tool in the diagnosis and management of asthma. More research is needed to support its routine clinical use.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculous pleuritis: clinical presentations and diagnostic challenges. 结核性胸膜炎:临床表现和诊断难题。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-06 DOI: 10.1097/MCP.0000000000001052
Ken Ka Pang Chan, Yun Chor Gary Lee

Purpose of review: Tuberculous pleuritis (TBP) is one of the most common types of extrapulmonary tuberculosis. We highlight the latest epidemiology of TBP, the heterogeneity of its presentation and the performance of different diagnostic strategies.

Recent findings: There are differential trends in the incidences of TBP worldwide. Its incidence increased in China but decreased in the United States in the past decade. The presentation of TBP is heterogeneous regarding clinical symptoms, radiological findings and pleural fluid analysis results. Conventional microbiological tests have low sensitivities to diagnose TBP. Recent research focused on various diagnostic tools with better yield. The sensitivity of nucleic acid amplification tests (NAAT) in pleural fluid, including the latest generation of PCR and sequencing-based techniques for detecting tuberculosis, remains suboptimal. Various pleural fluid biomarkers have been explored, but there is a lack of consensus on their clinical utility and cutoff levels.

Summary: The heterogeneity of clinical presentation poses obstacles to diagnosing TBP. Further development of diagnostic tools, including more robust NAAT and biomarkers with additional validation, is needed before incorporation into routine clinical practice.

审查目的:结核性胸膜炎(TBP)是肺外结核最常见的类型之一。我们重点介绍了 TBP 的最新流行病学、其表现的异质性以及不同诊断策略的效果:全球肺结核发病率呈现不同趋势。过去十年中,中国的发病率有所上升,但美国的发病率有所下降。TBP 的临床症状、放射学检查结果和胸腔积液分析结果各不相同。传统的微生物检测对 TBP 的诊断灵敏度较低。近期研究的重点是各种具有更高灵敏度的诊断工具。胸腔积液中的核酸扩增检测(NAAT),包括最新一代的 PCR 和基于测序的结核病检测技术,其灵敏度仍不理想。摘要:临床表现的异质性给结核病的诊断带来了障碍。在将 TBP 纳入常规临床实践之前,需要进一步开发诊断工具,包括更强大的 NAAT 和经过进一步验证的生物标志物。
{"title":"Tuberculous pleuritis: clinical presentations and diagnostic challenges.","authors":"Ken Ka Pang Chan, Yun Chor Gary Lee","doi":"10.1097/MCP.0000000000001052","DOIUrl":"10.1097/MCP.0000000000001052","url":null,"abstract":"<p><strong>Purpose of review: </strong>Tuberculous pleuritis (TBP) is one of the most common types of extrapulmonary tuberculosis. We highlight the latest epidemiology of TBP, the heterogeneity of its presentation and the performance of different diagnostic strategies.</p><p><strong>Recent findings: </strong>There are differential trends in the incidences of TBP worldwide. Its incidence increased in China but decreased in the United States in the past decade. The presentation of TBP is heterogeneous regarding clinical symptoms, radiological findings and pleural fluid analysis results. Conventional microbiological tests have low sensitivities to diagnose TBP. Recent research focused on various diagnostic tools with better yield. The sensitivity of nucleic acid amplification tests (NAAT) in pleural fluid, including the latest generation of PCR and sequencing-based techniques for detecting tuberculosis, remains suboptimal. Various pleural fluid biomarkers have been explored, but there is a lack of consensus on their clinical utility and cutoff levels.</p><p><strong>Summary: </strong>The heterogeneity of clinical presentation poses obstacles to diagnosing TBP. Further development of diagnostic tools, including more robust NAAT and biomarkers with additional validation, is needed before incorporation into routine clinical practice.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung abscess: an update on the current knowledge and call for future investigations. 肺脓肿:现有知识的更新和未来研究的呼吁。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-19 DOI: 10.1097/MCP.0000000000001058
Søren Sperling, Victor Naestholt Dahl, Andreas Fløe

Purpose of review: Lung abscess is a severe and complex respiratory infection. The purpose of this review is to discuss recent publications on lung abscess, covering topics such as epidemiology, clinical presentation, diagnosis, and treatment and prevention.

Recent findings: Risk factors associated with lung abscess include structural lung disease, poor dental hygiene, and ventilator-associated pneumonia, while concerns are now raised regarding the potential of electronic cigarettes use as a risk factor. The complexity of lung abscess is reflected by the relative high number of case reports describing rare and complex cases. Early transthoracic drainage could improve in-hospital outcomes, while next-generation sequencing could become an important tool in diagnostics and future clinical studies.

Summary: High-quality evidence and guidelines to support treatment of lung abscess are lacking. Despite advancements, we call for prospective studies to evaluate the use of invasive procedures and antibiotic treatment regimens.

审查目的:肺脓肿是一种严重而复杂的呼吸道感染。本综述旨在讨论最近发表的有关肺脓肿的文章,涉及的主题包括流行病学、临床表现、诊断以及治疗和预防:与肺脓肿相关的风险因素包括肺部结构性疾病、牙科卫生不良和呼吸机相关肺炎,而使用电子香烟作为风险因素的可能性也引起了关注。描述罕见和复杂病例的病例报告相对较多,这反映了肺脓肿的复杂性。早期经胸引流可改善院内预后,而下一代测序可能成为诊断和未来临床研究的重要工具。摘要:目前缺乏支持肺脓肿治疗的高质量证据和指南。尽管取得了进展,但我们仍呼吁开展前瞻性研究,以评估侵入性手术和抗生素治疗方案的使用情况。
{"title":"Lung abscess: an update on the current knowledge and call for future investigations.","authors":"Søren Sperling, Victor Naestholt Dahl, Andreas Fløe","doi":"10.1097/MCP.0000000000001058","DOIUrl":"10.1097/MCP.0000000000001058","url":null,"abstract":"<p><strong>Purpose of review: </strong>Lung abscess is a severe and complex respiratory infection. The purpose of this review is to discuss recent publications on lung abscess, covering topics such as epidemiology, clinical presentation, diagnosis, and treatment and prevention.</p><p><strong>Recent findings: </strong>Risk factors associated with lung abscess include structural lung disease, poor dental hygiene, and ventilator-associated pneumonia, while concerns are now raised regarding the potential of electronic cigarettes use as a risk factor. The complexity of lung abscess is reflected by the relative high number of case reports describing rare and complex cases. Early transthoracic drainage could improve in-hospital outcomes, while next-generation sequencing could become an important tool in diagnostics and future clinical studies.</p><p><strong>Summary: </strong>High-quality evidence and guidelines to support treatment of lung abscess are lacking. Despite advancements, we call for prospective studies to evaluate the use of invasive procedures and antibiotic treatment regimens.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic. 生物制剂时代导致哮喘恶化的病毒感染和 COVID-19 大流行。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-26 DOI: 10.1097/MCP.0000000000001061
Pedro A Lamothe, Violeta Capric, F Eun-Hyung Lee

Purpose of review: Asthma exacerbations are associated with substantial symptom burden and healthcare costs. Viral infections are the most common identified cause of asthma exacerbations. The epidemiology of viral respiratory infections has undergone a significant evolution during the COVID-19 pandemic. The relationship between viruses and asthmatic hosts has long been recognized but it is still incompletely understood. The use of newly approved asthma biologics has helped us understand this interaction better.

Recent findings: We review recent updates on the interaction between asthma and respiratory viruses, and we address how biologics and immunotherapies could affect this relationship by altering the respiratory mucosa cytokine milieu. By exploring the evolving epidemiological landscape of viral infections during the different phases of the COVID-19 pandemic, we emphasize the early post-pandemic stage, where a resurgence of pre-pandemic viruses with atypical seasonality patterns occurred. Finally, we discuss the newly developed RSV and SARS-CoV-2 vaccines and how they reduce respiratory infections.

Summary: Characterizing how respiratory viruses interact with asthmatic hosts will allow us to identify tailored therapies to reduce the burden of asthma exacerbations. New vaccination strategies are likely to shape the future viral asthma exacerbation landscape.

审查目的:哮喘加重与严重的症状负担和医疗费用有关。病毒感染是导致哮喘加重的最常见原因。在 COVID-19 大流行期间,病毒性呼吸道感染的流行病学发生了重大变化。病毒与哮喘宿主之间的关系早已得到公认,但人们对这种关系的了解仍不全面。新批准的哮喘生物制剂的使用有助于我们更好地理解这种相互作用:我们回顾了哮喘与呼吸道病毒之间相互作用的最新进展,并探讨了生物制剂和免疫疗法如何通过改变呼吸道粘膜细胞因子环境来影响这种关系。通过探讨 COVID-19 大流行不同阶段病毒感染流行病学的演变情况,我们强调了大流行后的早期阶段,在这一阶段,大流行前的病毒以非典型的季节性模式卷土重来。最后,我们讨论了新开发的 RSV 和 SARS-CoV-2 疫苗,以及它们如何减少呼吸道感染。摘要:了解呼吸道病毒如何与哮喘宿主相互作用将使我们能够确定有针对性的疗法,以减轻哮喘加重的负担。新的疫苗接种策略很可能会塑造未来病毒性哮喘加重的格局。
{"title":"Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic.","authors":"Pedro A Lamothe, Violeta Capric, F Eun-Hyung Lee","doi":"10.1097/MCP.0000000000001061","DOIUrl":"10.1097/MCP.0000000000001061","url":null,"abstract":"<p><strong>Purpose of review: </strong>Asthma exacerbations are associated with substantial symptom burden and healthcare costs. Viral infections are the most common identified cause of asthma exacerbations. The epidemiology of viral respiratory infections has undergone a significant evolution during the COVID-19 pandemic. The relationship between viruses and asthmatic hosts has long been recognized but it is still incompletely understood. The use of newly approved asthma biologics has helped us understand this interaction better.</p><p><strong>Recent findings: </strong>We review recent updates on the interaction between asthma and respiratory viruses, and we address how biologics and immunotherapies could affect this relationship by altering the respiratory mucosa cytokine milieu. By exploring the evolving epidemiological landscape of viral infections during the different phases of the COVID-19 pandemic, we emphasize the early post-pandemic stage, where a resurgence of pre-pandemic viruses with atypical seasonality patterns occurred. Finally, we discuss the newly developed RSV and SARS-CoV-2 vaccines and how they reduce respiratory infections.</p><p><strong>Summary: </strong>Characterizing how respiratory viruses interact with asthmatic hosts will allow us to identify tailored therapies to reduce the burden of asthma exacerbations. New vaccination strategies are likely to shape the future viral asthma exacerbation landscape.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remission in asthma. 哮喘缓解
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-03-05 DOI: 10.1097/MCP.0000000000001068
Marek Lommatzsch

Purpose of review: To review the current concepts of remission in asthma.

Recent findings: Until 2023, asthma guidelines have been promoting the concept of disease control, recommending the step-wise addition of drugs until the best possible disease control is achieved. With the advent of highly effective, anti-inflammatory disease-modifying antiasthmatic drugs (DMAADs), treatment goals of asthma have changed. Several national guidelines have now announced remission as a general treatment goal in asthma. Currently, all guidelines agree that asthma remission is defined by the presence of at least three characteristics over a period of at least one 1 year: absence of exacerbations, no systemic corticosteroid use for the treatment of asthma and minimal asthma-related symptoms. In the future, a generally accepted, evidence-based and easy-to-use definition of remission will be needed for daily clinical practice. It is clear, however, that precise phenotyping (including measurement of biomarkers) is an essential prerequisite to achieve clinical remission in each individual patient.

Summary: Remission has been included as the treatment goal in asthma in several national guidelines, reflecting the paradigm shift in asthma, from short-term symptom control to long-term symptom prevention. An international consensus on the criteria for asthma remission is expected in the near future.

综述目的:回顾当前哮喘缓解的概念:直到 2023 年,哮喘指南一直在推广疾病控制的概念,建议逐步增加药物,直到达到最佳的疾病控制效果。随着高效抗炎的改变病情抗哮喘药物(DMAADs)的出现,哮喘的治疗目标发生了变化。目前,一些国家的指南已宣布将缓解作为哮喘的总体治疗目标。目前,所有指南都认为,哮喘缓解的定义是在至少 1 年的时间内至少具备以下三个特征:无病情加重、未使用皮质类固醇治疗哮喘以及哮喘相关症状极少。未来,在日常临床实践中将需要一个普遍接受、以证据为基础且易于使用的缓解定义。但很明显,精确的表型分析(包括生物标志物的测量)是每个患者实现临床缓解的必要前提:一些国家的指南已将缓解作为哮喘的治疗目标,这反映了哮喘治疗模式的转变,即从短期症状控制转向长期症状预防。国际社会有望在不久的将来就哮喘缓解的标准达成共识。
{"title":"Remission in asthma.","authors":"Marek Lommatzsch","doi":"10.1097/MCP.0000000000001068","DOIUrl":"10.1097/MCP.0000000000001068","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the current concepts of remission in asthma.</p><p><strong>Recent findings: </strong>Until 2023, asthma guidelines have been promoting the concept of disease control, recommending the step-wise addition of drugs until the best possible disease control is achieved. With the advent of highly effective, anti-inflammatory disease-modifying antiasthmatic drugs (DMAADs), treatment goals of asthma have changed. Several national guidelines have now announced remission as a general treatment goal in asthma. Currently, all guidelines agree that asthma remission is defined by the presence of at least three characteristics over a period of at least one 1 year: absence of exacerbations, no systemic corticosteroid use for the treatment of asthma and minimal asthma-related symptoms. In the future, a generally accepted, evidence-based and easy-to-use definition of remission will be needed for daily clinical practice. It is clear, however, that precise phenotyping (including measurement of biomarkers) is an essential prerequisite to achieve clinical remission in each individual patient.</p><p><strong>Summary: </strong>Remission has been included as the treatment goal in asthma in several national guidelines, reflecting the paradigm shift in asthma, from short-term symptom control to long-term symptom prevention. An international consensus on the criteria for asthma remission is expected in the near future.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma in pregnancy: a review of recent literature. 妊娠期哮喘:最新文献综述。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-03-13 DOI: 10.1097/MCP.0000000000001072
Kelly Colas, Jennifer Namazy

Purpose of review: Asthma remains the most common respiratory disease in pregnancy. Identifying risk factors for asthma exacerbations during pregnancy is critical, as uncontrolled asthma can have detrimental effects for both mother and baby. In this review, we discuss recent literature exploring risk factors, fetal and maternal effects, and treatment options for asthma during pregnancy.

Recent findings: Recent literature suggests that optimizing asthma during pregnancy improves outcomes for both mother and baby, as well as later in childhood. Current research affirms that the benefit of asthma medication use outweighs any potential risks related to the medications themselves. Limited information is available regarding the use of newer therapies such as biologics during pregnancy.

Summary: Identifying risk factors for asthma exacerbations during pregnancy is critical to prevent adverse outcomes for both mother and baby. Recent evidence continues to affirm the safety of asthma medication use; more studies are needed regarding the use of new therapies during pregnancy.

审查目的:哮喘仍然是孕期最常见的呼吸系统疾病。确定孕期哮喘加重的风险因素至关重要,因为哮喘如果得不到控制,会对母婴造成不利影响。在这篇综述中,我们讨论了探讨妊娠期哮喘的风险因素、对胎儿和母体的影响以及治疗方案的最新文献:最新研究结果:最新文献表明,优化孕期哮喘治疗可改善母婴及儿童期的预后。目前的研究证实,使用哮喘药物的益处大于与药物本身相关的任何潜在风险。有关孕期使用生物制剂等新疗法的信息有限。摘要:识别孕期哮喘加重的风险因素对于预防母婴不良后果至关重要。最近的证据继续肯定了哮喘用药的安全性;关于孕期使用新疗法,还需要进行更多的研究。
{"title":"Asthma in pregnancy: a review of recent literature.","authors":"Kelly Colas, Jennifer Namazy","doi":"10.1097/MCP.0000000000001072","DOIUrl":"10.1097/MCP.0000000000001072","url":null,"abstract":"<p><strong>Purpose of review: </strong>Asthma remains the most common respiratory disease in pregnancy. Identifying risk factors for asthma exacerbations during pregnancy is critical, as uncontrolled asthma can have detrimental effects for both mother and baby. In this review, we discuss recent literature exploring risk factors, fetal and maternal effects, and treatment options for asthma during pregnancy.</p><p><strong>Recent findings: </strong>Recent literature suggests that optimizing asthma during pregnancy improves outcomes for both mother and baby, as well as later in childhood. Current research affirms that the benefit of asthma medication use outweighs any potential risks related to the medications themselves. Limited information is available regarding the use of newer therapies such as biologics during pregnancy.</p><p><strong>Summary: </strong>Identifying risk factors for asthma exacerbations during pregnancy is critical to prevent adverse outcomes for both mother and baby. Recent evidence continues to affirm the safety of asthma medication use; more studies are needed regarding the use of new therapies during pregnancy.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent developments in occupational asthma. 职业性哮喘的最新进展。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-28 DOI: 10.1097/MCP.0000000000001062
Claudia Blouin, Catherine Lemière

Purpose of review: Occupational asthma (OA) is a complex condition that can be difficult to diagnose. The purpose of this review is to describe some recent findings regarding the epidemiology of OA, the occupational sensitizing agents, the prognosis of OA, and its primary prevention.

Recent findings: The risk of developing OA varies according to the geographic localization of the worker, the type of industry and the type of sensitizing agents. New findings have been reported for several known sensitizing agents, such as isocyanates, seafood & cleaning agents, and their related industries, such as hairdressing salons and schools. Moreover, a few new sensitizing agents, such as cannabis, have been identified in the past few years. The prognosis of OA seems worse than that of nonwork-related asthma. It is mainly determined by the duration and the level of exposure. Primary prevention is crucial to reduce the number of new cases of OA. Complete avoidance of exposure to the causal agent remains the optimal treatment of sensitizer-induced OA.

Summary: Improving our knowledge regarding OA and its causative agents is key to enable an early recognition of this condition and improve its prognosis. Further research is still needed to improve primary prevention.

本综述的目的:职业性哮喘(OA)是一种难以诊断的复杂疾病。本综述旨在介绍有关职业性哮喘的流行病学、职业致敏因素、职业性哮喘的预后及其一级预防的一些最新发现:罹患 OA 的风险因工人的地理位置、行业类型和致敏剂类型而异。一些已知的致敏剂,如异氰酸酯、海鲜和清洁剂,以及与之相关的行业,如美发沙龙和学校,都有新的发现。此外,过去几年还发现了一些新的致敏物质,如大麻。OA 的预后似乎比非工作相关性哮喘更差。这主要取决于接触的时间长短和程度。初级预防对于减少 OA 新发病例至关重要。小结:提高我们对 OA 及其致病因子的认识是早期识别这种疾病并改善其预后的关键。仍需进一步研究,以改善初级预防。
{"title":"Recent developments in occupational asthma.","authors":"Claudia Blouin, Catherine Lemière","doi":"10.1097/MCP.0000000000001062","DOIUrl":"10.1097/MCP.0000000000001062","url":null,"abstract":"<p><strong>Purpose of review: </strong>Occupational asthma (OA) is a complex condition that can be difficult to diagnose. The purpose of this review is to describe some recent findings regarding the epidemiology of OA, the occupational sensitizing agents, the prognosis of OA, and its primary prevention.</p><p><strong>Recent findings: </strong>The risk of developing OA varies according to the geographic localization of the worker, the type of industry and the type of sensitizing agents. New findings have been reported for several known sensitizing agents, such as isocyanates, seafood & cleaning agents, and their related industries, such as hairdressing salons and schools. Moreover, a few new sensitizing agents, such as cannabis, have been identified in the past few years. The prognosis of OA seems worse than that of nonwork-related asthma. It is mainly determined by the duration and the level of exposure. Primary prevention is crucial to reduce the number of new cases of OA. Complete avoidance of exposure to the causal agent remains the optimal treatment of sensitizer-induced OA.</p><p><strong>Summary: </strong>Improving our knowledge regarding OA and its causative agents is key to enable an early recognition of this condition and improve its prognosis. Further research is still needed to improve primary prevention.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management. 耐多药结核病:关于流行病学、快速诊断和管理的最新观点。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-03-15 DOI: 10.1097/MCP.0000000000001070
Peter S Nyasulu, Cheick Oumar Doumbia, Veranyuy Ngah, Antieme Combo Georges Togo, Bassirou Diarra, Gershom Chongwe

Purpose of review: This review addresses the escalating global challenge of multidrug-resistant tuberculosis (MDR-TB) in Sub-Saharan Africa, with a focus on its complex comorbidity with HIV/AIDS. Emphasizing the urgency of the issue, the review aims to shed light on the unique healthcare landscape shaped by the convergence of high prevalence rates and intersecting complexities with HIV/AIDS in the region.

Recent findings: A notable increase in MDR-TB cases across Sub-Saharan Africa is attributed to challenges in timely diagnoses, treatment initiation, and patient treatment defaulting. The literature underscores the critical need for proactive measures to address diagnostic and treatment gaps associated with MDR-TB, particularly concerning its comorbidity with HIV/AIDS.

Summary: To effectively manage MDR-TB and its co-morbidity with HIV/AIDS, proactive screening programs are imperative. The review highlights the necessity of active follow-up strategies to ensure treatment adherence and reduce default rates, offering evidence-based insights for improved disease management in the region.

综述的目的:本综述探讨了撒哈拉以南非洲地区不断升级的耐多药结核病(MDR-TB)这一全球性挑战,重点关注其与艾滋病毒/艾滋病的复杂并发症。本综述强调了这一问题的紧迫性,旨在揭示该地区高发病率和与艾滋病毒/艾滋病相互交织的复杂性所形成的独特医疗保健格局:撒哈拉以南非洲地区的耐药结核病例明显增加,原因是在及时诊断、开始治疗和患者不接受治疗方面存在挑战。文献强调,亟需采取积极主动的措施,解决与 MDR-TB 相关的诊断和治疗差距问题,尤其是在 MDR-TB 与艾滋病毒/艾滋病并发症方面。摘要:为有效管理 MDR-TB 及其与艾滋病毒/艾滋病并发症,必须实施积极主动的筛查计划。这篇综述强调了积极的随访策略对确保坚持治疗和降低违约率的必要性,为改善该地区的疾病管理提供了循证见解。
{"title":"Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management.","authors":"Peter S Nyasulu, Cheick Oumar Doumbia, Veranyuy Ngah, Antieme Combo Georges Togo, Bassirou Diarra, Gershom Chongwe","doi":"10.1097/MCP.0000000000001070","DOIUrl":"10.1097/MCP.0000000000001070","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review addresses the escalating global challenge of multidrug-resistant tuberculosis (MDR-TB) in Sub-Saharan Africa, with a focus on its complex comorbidity with HIV/AIDS. Emphasizing the urgency of the issue, the review aims to shed light on the unique healthcare landscape shaped by the convergence of high prevalence rates and intersecting complexities with HIV/AIDS in the region.</p><p><strong>Recent findings: </strong>A notable increase in MDR-TB cases across Sub-Saharan Africa is attributed to challenges in timely diagnoses, treatment initiation, and patient treatment defaulting. The literature underscores the critical need for proactive measures to address diagnostic and treatment gaps associated with MDR-TB, particularly concerning its comorbidity with HIV/AIDS.</p><p><strong>Summary: </strong>To effectively manage MDR-TB and its co-morbidity with HIV/AIDS, proactive screening programs are imperative. The review highlights the necessity of active follow-up strategies to ensure treatment adherence and reduce default rates, offering evidence-based insights for improved disease management in the region.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Keeping global focus on the many challenges of respiratory tract infections. 让全球关注呼吸道感染的诸多挑战。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-03-26 DOI: 10.1097/MCP.0000000000001066
Alimuddin Zumla, David S Hui
{"title":"Keeping global focus on the many challenges of respiratory tract infections.","authors":"Alimuddin Zumla, David S Hui","doi":"10.1097/MCP.0000000000001066","DOIUrl":"10.1097/MCP.0000000000001066","url":null,"abstract":"","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140183993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung infections due to emerging fungal pathogens. 新出现的真菌病原体导致的肺部感染。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-15 DOI: 10.1097/MCP.0000000000001059
Francisco J Machiavello Roman, Lauren Pischel, Marwan M Azar

Purpose of review: This review highlights the epidemiology, pathogenesis and clinical management of pulmonary infections caused by emerging fungal organisms.

Recent findings: Emerging fungal infections have arisen as a result of population and environmental changes. An enlarging pool of immunocompromised hosts on triazole antifungal prophylaxis has led to an increased incidence of non- Aspergillus molds, such as Fusarium , Scedosporium and Lomentospora spp. Advances in diagnostic capabilities led to the identification of the Emergomyces genus and non- dermatitidis Blastomyces species, which have a significant disease burden in Africa and the Middle East. Climate change has contributed to changing the distribution of previously confined endemic mycoses, like coccidioidomycosis and talaromycosis. These emerging organisms pose important diagnostic and therapeutic challenges.

Summary: Newly recognized pathogenic fungi and established endemic mycoses with expanding geographic boundaries have become important agents of pulmonary disease. There is a dearth of clinical evidence on the appropriate management of these infections.

综述的目的:这篇综述重点介绍了新发真菌引起的肺部感染的流行病学、发病机制和临床治疗:新出现的真菌感染是人口和环境变化的结果。使用三唑类抗真菌药物预防的免疫力低下的宿主群体不断扩大,导致非曲霉霉菌(如镰刀菌属、镰孢菌属和洛门托孢菌属)的发病率增加。诊断能力的提高导致了新发霉属和非皮炎高分枝霉菌的鉴定,这些霉菌在非洲和中东地区造成了严重的疾病负担。气候变化改变了球孢子菌病和滑真菌病等以前局限的地方性真菌病的分布。摘要:新发现的致病真菌和已确定的地方真菌病的地理分布范围不断扩大,已成为肺部疾病的重要病原体。关于这些感染的适当治疗方法,目前还缺乏临床证据。
{"title":"Lung infections due to emerging fungal pathogens.","authors":"Francisco J Machiavello Roman, Lauren Pischel, Marwan M Azar","doi":"10.1097/MCP.0000000000001059","DOIUrl":"10.1097/MCP.0000000000001059","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review highlights the epidemiology, pathogenesis and clinical management of pulmonary infections caused by emerging fungal organisms.</p><p><strong>Recent findings: </strong>Emerging fungal infections have arisen as a result of population and environmental changes. An enlarging pool of immunocompromised hosts on triazole antifungal prophylaxis has led to an increased incidence of non- Aspergillus molds, such as Fusarium , Scedosporium and Lomentospora spp. Advances in diagnostic capabilities led to the identification of the Emergomyces genus and non- dermatitidis Blastomyces species, which have a significant disease burden in Africa and the Middle East. Climate change has contributed to changing the distribution of previously confined endemic mycoses, like coccidioidomycosis and talaromycosis. These emerging organisms pose important diagnostic and therapeutic challenges.</p><p><strong>Summary: </strong>Newly recognized pathogenic fungi and established endemic mycoses with expanding geographic boundaries have become important agents of pulmonary disease. There is a dearth of clinical evidence on the appropriate management of these infections.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1